TLR6 Blocking Peptide for STJ503303 is synthetically produced from the 195-225 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 195-225 on human TLR6 protein.
Immunogen Region
195-225
Specificity
This blocking peptide is recommended for use in combination with TLR6 antibody, STJ503303
Additional Info
Tissue Specificity
Detected in monocytes, CD11c+ immature dendritic cells, plasmacytoid pre-dendritic cells and dermal microvessel endothelial cells.
Function
Participates in the innate immune response to Gram-positive bacteria and fungi. Specifically recognizes diacylated and, to a lesser extent, triacylated lipopeptides. In response to diacylated lipopeptides, forms the activation cluster TLR2:TLR6:CD14:CD36, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR2. In complex with TLR4, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion.
Cell MembraneSingle-Pass Type I Membrane ProteinCytoplasmic VesiclePhagosome MembraneMembrane RaftGolgi ApparatusUpon Complex Formation With Cd36 And Tlr4Internalized Through Dynamin-Dependent EndocytosisDoes Not Reside In Lipid Rafts Before Stimulation But Accumulates Increasingly In The Raft Upon The Presence Of The Microbial LigandIn Response To Diacylated LipoproteinsTlr2:Tlr6 Heterodimers Are Recruited In Lipid RaftsThis Recruitment Determine The Intracellular Targeting To The Golgi Apparatus
Alternative Peptide Names
Toll-Like Receptor 6 proteinCd Antigen Cd286 proteinTLR6 protein
